These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Rapid screening for Mamu-A1-positive rhesus macaques using a SIVmac Gag peptide-specific cytotoxic T-lymphocyte assay.
    Author: Vogel T, Norley S, Beer B, Kurth R.
    Journal: Immunology; 1995 Mar; 84(3):482-7. PubMed ID: 7751033.
    Abstract:
    As part of an ongoing vaccine study using peptide immunogens designed to stimulate simian immunodeficiency virus (SIV)mac-specific cytotoxic T lymphocytes (CTL) it was necessary to identify rhesus macaques within our colony bearing the Mamu-A1 major histocompatibility complex (MHC) class I haplotype. Peripheral blood mononuclear cells (PBMC) from individual monkeys were analysed by immunoelectrofocusing for the presence of a band corresponding to the Mamu-A1 molecule. In addition, PBMC were pulsed with the SIVmac Gag peptide 11 (against which CTL are Mamu-A1 restricted) and analysed for susceptibility to lysis by peptide 11-specific CTL. PBMC from all of the rhesus macaques shown to be Mamu-A1 positive by immunoelectrofocusing were highly sensitive to lysis by the peptide 11-specific CTL. A total of 46% (16 from 35) of the rhesus macaques originating from India were found to be Mamu-A1 positive, whereas none of the Chinese rhesus (0 from 37) macaques possessed this haplotype. Once a peptide-specific CTL is established, screening by CTL assay offers a faster, reliable and more relevant alternative to immunoelectrofocusing for selecting monkeys for use in vaccination trials.
    [Abstract] [Full Text] [Related] [New Search]